Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Increased Protein Turnover Contributes to the Development of Pulmonary Fibrosis

27.07.2015

Scientists of the Comprehensive Pneumology Center (CPC) at the Helmholtz Zentrum München have identified a new mechanism which contributes to the development of idiopathic pulmonary fibrosis (IPF). They showed that the pathological changes of lung tissue are accompanied by an increase in protein turnover by the central protein degradation machinery of the cell – the proteasome. Their study has now been published in the ‘American Journal of Respiratory and Critical Care Medicine’.

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death.

Connective tissue is mainly produced by myofibroblasts. The research group led by PD Dr. Silke Meiners of the Institute of Lung Biology and the CPC showed now for the first time that the activation of these myofibroblasts depends on increased protein turnover by the 26S proteasome*.

Inhibition of the proteasome as a possible therapeutic approach

In the recently published study, the Helmholtz scientists were able to demonstrate an activation of the 26S proteasome during the transformation of normal fibroblasts into myofibroblasts both in vitro and in vivo using two different experimental models of pulmonary fibrosis. Moreover, increased protein turnover was also detected in fibrotic lung tissue of IPF patients.

“Conversely, we were able to show that targeted inhibition of the 26S proteasome prevents the differentiation of primary human lung fibroblasts into myofibroblasts, confirming the essential role of enhanced proteasomal protein degradation for this pathological process,” said Silke Meiners.

“Understanding the mechanisms that lead to a disease such as IPF helps us identify innovative approaches that allow therapeutic intervention,” comments Professor Oliver Eickelberg, director of the Institute of Lung Biology and scientific director of the CPC. In further studies, the Helmholtz scientists want to test the therapeutic use of substances which specifically inhibit the 26S proteasome, but do not affect other proteasome complexes in the cell**.

Furthermore, the lung researchers speculate that activation of the 26S proteasome may generally occur in fibrotic diseases, such as heart and kidney fibrosis, since differentiation of fibroblasts into myofibroblasts also is the underlying mechanism for the pathological alterations in these disorders.
Further Information

Background:
* The 26S proteasome is a kind of molecular shredder that breaks down old or defective proteins of the cell into their recyclable components. It consists of a catalytic core, the 20S proteasome, and one or two 19S regulators that bind to both ends of the 20S complex and mediate specific degradation of ubiquitin-tagged proteins. It is assumed that a majority of the proteins in the cell are degraded in this way.

**As shown in the study, by use of siRNA, which targeted a specific, essential subunit of the 19S regulator, the targeted inhibition of the 26S proteasome successfully suppressed a differentiation of fibroblasts into pathological myofibroblasts. This approach is significantly more specific than the use of catalytic proteasome inhibitors, which inhibit all active proteasomes, that is 26S and 20S proteasome complexes, in an entirely non-targeted way. Apart from their use to treat malignant tumor diseases, proteasome inhibitors are controversial because of their toxic side effects.

The specific inhibition of the 26S proteasome here represents a novel and far more specific approach through which unwanted side effects could be reduced, since preferably cells are attacked that show an activation of the system. In further studies, the scientists want to test the therapeutic use of substances that interfere specifically with 26S proteasome activity. These are molecules that prevent the assembly of the high-molecular-weight 26S proteasome from the 20S complex and the 19S regulators. Furthermore, a compound screening is planned for new substances that induce a specific 26S proteasome inhibition.

Original publication:
Semren, N. et al. (2015). Regulation of 26S proteasome activity in pulmonary fibrosis, American Journal of Respiratory and Critical Care Medicine, DOI: 10.1164/rccm.201412-2270OC

As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.

The Comprehensive Pneumology Center (CPC) is a joint research project of the Helmholtz Zentrum München, the Ludwig-Maximilians-Universität with its University Hospital and the Asklepios Fachkliniken München-Gauting. The CPC's objective is to conduct research on chronic lung diseases in order to develop new diagnosis and therapy strategies. The CPC maintains a focus on experimental pneumology with the investigation of cellular, molecular and immunological mechanisms involved in lung diseases. The CPC is one of five sites of the German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL.

Contact for the media:
Department of Communication, Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg - Phone: +49 89 3187 2238 - Fax: +49 89 3187 3324 – E-mail: presse@helmholtz-muenchen.de

Scientific contact at Helmholtz Zentrum München:
PD Dr. Silke Meiners, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Institut für Lungenbiologie, Ingolstädter Landstr. 1, 85764 Neuherberg – Phone: +49 89 3187 4673 - E-mail: silke.meiners@helmholtz-muenchen.de

Weitere Informationen:

http://www.ncbi.nlm.nih.gov/pubmed/26207697 - Link to the publication
http://www.helmholtz-muenchen.de/en/news/press-releases/2015/index.html - Press Releases Helmholtz Zentrum München
http://www.helmholtz-muenchen.de/ilbd/index.html - Website CPC

Kommunikation | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

More articles from Life Sciences:

nachricht Lethal combination: Drug cocktail turns off the juice to cancer cells
12.12.2018 | Universität Basel

nachricht Smelling the forest – not the trees
12.12.2018 | Universität Konstanz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

New discoveries predict ability to forecast dementia from single molecule

12.12.2018 | Health and Medicine

CCNY-Yale researchers make shape shifting cell breakthrough

12.12.2018 | Physics and Astronomy

Pain: Perception and motor impulses arise in the brain independently of one another

12.12.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>